JP2011502177A - ペプチドリガンドによる指向性ドラッグデリバリー - Google Patents

ペプチドリガンドによる指向性ドラッグデリバリー Download PDF

Info

Publication number
JP2011502177A
JP2011502177A JP2010532406A JP2010532406A JP2011502177A JP 2011502177 A JP2011502177 A JP 2011502177A JP 2010532406 A JP2010532406 A JP 2010532406A JP 2010532406 A JP2010532406 A JP 2010532406A JP 2011502177 A JP2011502177 A JP 2011502177A
Authority
JP
Japan
Prior art keywords
seq
liposome
peptide
lipid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010532406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502177A5 (enExample
Inventor
ユホン シュー
シュシアン ソン
ダン リュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jiao Tong University
Original Assignee
Shanghai Jiao Tong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jiao Tong University filed Critical Shanghai Jiao Tong University
Publication of JP2011502177A publication Critical patent/JP2011502177A/ja
Publication of JP2011502177A5 publication Critical patent/JP2011502177A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2010532406A 2007-11-05 2008-11-05 ペプチドリガンドによる指向性ドラッグデリバリー Pending JP2011502177A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2007/003129 WO2009059450A1 (en) 2007-11-05 2007-11-05 Peptide ligand directed drug delivery
PCT/CN2008/001847 WO2009062399A1 (en) 2007-11-05 2008-11-05 Peptide ligand directed drug delivery

Publications (2)

Publication Number Publication Date
JP2011502177A true JP2011502177A (ja) 2011-01-20
JP2011502177A5 JP2011502177A5 (enExample) 2011-12-22

Family

ID=40625344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010532406A Pending JP2011502177A (ja) 2007-11-05 2008-11-05 ペプチドリガンドによる指向性ドラッグデリバリー

Country Status (5)

Country Link
US (1) US20110200527A1 (enExample)
EP (1) EP2215107B1 (enExample)
JP (1) JP2011502177A (enExample)
CN (1) CN101855237B (enExample)
WO (2) WO2009059450A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015507019A (ja) * 2012-02-17 2015-03-05 セルシオン コーポレイション 感熱性ナノ粒子製剤およびその製造方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
GB0814960D0 (en) * 2008-08-15 2008-09-24 Ge Healthcare As Method for detecting dysplasia
WO2010088268A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
EP2391217A4 (en) 2009-01-28 2015-05-20 Smartcells Inc SYNTHETIC CONJUGATES AND ITS USE
SG173117A1 (en) 2009-01-28 2011-08-29 Smartcells Inc Crystalline insulin-conjugates
SG193837A1 (en) 2009-01-28 2013-10-30 Smartcells Inc Conjugate based systems for controlled drug delivery
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
JP6066732B2 (ja) 2010-03-05 2017-01-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
US9074015B2 (en) 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
CA2805739A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
AU2011282987A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
CN102351941B (zh) * 2011-06-08 2014-07-16 中国科学院上海应用物理研究所 对功能分子进行18f标记的方法
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
EP2718261B1 (en) * 2011-06-08 2016-02-24 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing sirna activity
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
US20130261444A1 (en) * 2012-03-28 2013-10-03 The Uab Research Foundation Photothermal nanostructures in tumor therapy
US9949927B2 (en) 2012-04-10 2018-04-24 The Regents Of The University Of California Bis-polymer lipid-peptide conjugates and nanoparticles thereof
RU2014144945A (ru) * 2012-04-10 2016-05-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Бис-полимерные липид-пептидные конъюгаты и наночастицы из них
CN102875647B (zh) * 2012-09-10 2014-11-19 上海交通大学 与cd40l蛋白特异性结合的配体多肽及药物输送系统
EP3024441A4 (en) * 2013-07-25 2017-04-19 Nemucore Medical Innovations, Inc. Nanoemulsions of hydrophobic platinum derivative
US9884125B2 (en) 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
CN104262455B (zh) * 2014-08-22 2017-05-03 亚飞（上海）生物医药科技有限公司 肿瘤微环境靶向激活的紫杉醇衍生物及其制备和用途
AU2015306574B2 (en) 2014-08-22 2020-07-23 Yafei Shanghai Biology Medicine Science & Technology Co. Ltd. Specifically activated micromolecular target coupling body in tumor microenvironment and use thereof
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
EP3265063A4 (en) 2015-03-03 2018-11-07 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN104825394B (zh) * 2015-04-17 2018-08-17 北京大学 靶向肿瘤相关成纤维细胞的脂质体载药系统
JP2018528257A (ja) * 2015-07-10 2018-09-27 ペプティノボ・バイオファーマ・リミテッド・ライアビリティ・カンパニーＰｅｐｔｉｎｏｖｏ Ｂｉｏｐｈａｒｍａ， ＬＬＣ 疎水性薬剤の効能を改善するための配合物
US10428111B2 (en) 2015-09-12 2019-10-01 Mahmoud Reza Jaafari Cancer targeting by anti-EGFR peptides and applications thereof
WO2017184133A1 (en) * 2016-04-20 2017-10-26 Hewlett-Packard Development Company, L.P. Material sets
CN110035766B9 (zh) * 2016-09-21 2023-12-15 新加坡科技研究局 用于抑制皮肤炎症和确定癌症易感性的方法和组合物
CN108635593B (zh) * 2018-05-21 2022-03-11 天津科技大学 一种e-选择素肽配体修饰的靶向热敏脂质体的制备和应用
CN111164068B (zh) 2018-08-21 2023-11-14 株式会社东芝 生物降解性化合物、脂质粒子、含有脂质粒子的组合物、及试剂盒
US20240148830A1 (en) * 2022-11-07 2024-05-09 Ocugen, Inc. Treatment of Neurological Disorder Using NHR

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146511A1 (en) * 2006-12-14 2008-06-19 Fundacao Oswaldo Cruz - Fiocruz Selection method of peptides, peptides, method and kit of infection identification by mycobacterium leprae, pharmaceutical or immunological compositions containing peptides of mycobacterium leprae or sequences functionally equivalent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
ES2312649T3 (es) * 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
RU2196604C1 (ru) * 2001-12-21 2003-01-20 Северин Евгений Сергеевич Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
US20040248800A1 (en) * 2003-03-20 2004-12-09 Shane Atwell Crystals and structures of epidermal growth factor receptor kinase domain
CN100356981C (zh) * 2004-03-31 2007-12-26 上海新世界基因技术开发有限公司 与人表皮生长因子受体egfr特异性结合的配体寡肽
CN100430092C (zh) * 2004-06-03 2008-11-05 上海交通大学 用于基因及多肽药物粘膜给药的脂质复合物及其制备方法
WO2007048121A2 (en) * 2005-10-20 2007-04-26 Centocor, Inc. Methods of preparing targeted immunoliposomes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146511A1 (en) * 2006-12-14 2008-06-19 Fundacao Oswaldo Cruz - Fiocruz Selection method of peptides, peptides, method and kit of infection identification by mycobacterium leprae, pharmaceutical or immunological compositions containing peptides of mycobacterium leprae or sequences functionally equivalent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013028358; Ａｍｉｔ　Ｋ．　Ｇａｌａｎｄｅ，　ｅｔ　ａｌ．: ＣｈｅｍＢｉｏＣｈｅｍ ６, 2005, ｐｐ．１９９１-１９９８ *
JPN6013028359; Ｚｏｎｇｈａｉ　Ｌｉ，　ｅｔ　ａｌ．: ＦＡＳＥＢ　Ｊ． １９, 2005, ｐｐ．１９７８-１９８５ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015507019A (ja) * 2012-02-17 2015-03-05 セルシオン コーポレイション 感熱性ナノ粒子製剤およびその製造方法
JP2018058858A (ja) * 2012-02-17 2018-04-12 セルシオン コーポレイション 感熱性ナノ粒子製剤およびその製造方法
US10251901B2 (en) 2012-02-17 2019-04-09 Celsion Corporation Thermosensitive nanoparticle formulations and method of making the same

Also Published As

Publication number Publication date
CN101855237B (zh) 2014-10-22
WO2009059450A1 (en) 2009-05-14
EP2215107A1 (en) 2010-08-11
US20110200527A1 (en) 2011-08-18
CN101855237A (zh) 2010-10-06
EP2215107A4 (en) 2010-10-27
WO2009062399A1 (en) 2009-05-22
EP2215107B1 (en) 2012-10-17

Similar Documents

Publication Publication Date Title
EP2215107B1 (en) Peptide ligand directed drug delivery
Obaid et al. Impacting pancreatic cancer therapy in heterotypic in vitro organoids and in vivo tumors with specificity-tuned, NIR-activable photoimmunonanoconjugates: towards conquering desmoplasia?
Guimarães et al. Nanoparticles for immune cytokine TRAIL-based cancer therapy
US11337924B2 (en) Targeted polymerized nanoparticles for cancer treatment
Li et al. Liposomes modified with bio-substances for cancer treatment
Song et al. Novel peptide ligand directs liposomes toward EGF‐R high‐expressing cancer cells in vitro and in vivo
US9801943B2 (en) Method for in vivo targeting of nanoparticles via bioorthogonal copper-free click chemistry
JP2025111567A (ja) ガンマポリグルタミン酸化ペメトレキセドおよびその使用
JP5676643B2 (ja) インターロイキン−４受容体を特異的に標的とするペプチドで標識されたリポソームを含有する癌診断又は治療用標的指向型薬物伝達システム、及びその製造方法
Tang et al. Effects of surface displayed targeting ligand GE11 on liposome distribution and extravasation in tumor
JP2008533157A (ja) 疾患および障害の診断および処置のためのナノセル
US20190192686A1 (en) Targeted nanodroplet emulsions for treating cancer
Shin et al. A nanotherapeutic approach to selectively eliminate metastatic breast cancer cells by targeting cell surface GRP78
TWI630910B (zh) 供靶向、造影及治療前列腺癌之胜肽共軛奈米粒子
US20120258038A1 (en) Uses of apoptotic cell-targeting peptides, label substances and liposomes containing a therapeutic agent for preventing, treating or therapeutically diagnosing apoptosis-related diseases
TWI856109B (zh) 靶向表皮生長因子受體的配體及用於治療腫瘤的組合物
TW201018487A (en) Peptide ligand directed drug delivery
Luan A Cancer-targeting Liposomal Delivery System for Photodynamic Diagnosis and Therapy of Cancers in Peritoneal Cavity
Detampel Targeting of hepatocytes Using vector-conjugated liposomes: evaluation of targeting strategies
CA3090494A1 (en) Alpha polyglutamated pemetrexed and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131028